Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2023
Filter by date:
Showing 1262 press releases before 2023
-
AstraZeneca’s antibody combination, Evusheld▼ (tixagevimab co-packaged with cilgavimab) authorised for use in Great Britain for pre-exposure prophylaxis (prevention) of COVID-19
-
Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer
-
Update on US regulatory review of Fasenra in chronic rhinosinusitis with nasal polyps
-
Lynparza approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
-
Nirsevimab significantly protected infants against RSV disease in Phase III MELODY trial
-
AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement to develop and commercialise NI006
-
AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers
-
Enhertu significantly improved both progression-free and overall survival in DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer
-
Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants
-
Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus
Latest articles and press releases
All of our latest press releases and articles are available to explore
Use a maximum of two downloads here
